Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Asset Writedowns and Impairment (2021 - 2023)

Oncology Institute (TOI) has disclosed Asset Writedowns and Impairment for 3 consecutive years, with $2.0 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Asset Writedowns and Impairment rose 2587.84% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2024, up 1794.29%, and an annual FY2023 reading of $2.0 million, up 324.37% over the prior year.
  • Asset Writedowns and Impairment was $2.0 million for Q4 2023 at Oncology Institute, up from $33000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $2.0 million in Q4 2023 and bottomed at -$722000.0 in Q2 2021.
  • Average Asset Writedowns and Impairment over 3 years is $189000.0, with a median of $74000.0 recorded in 2022.
  • Peak annual rise in Asset Writedowns and Impairment hit 2587.84% in 2023, while the deepest fall reached 102.86% in 2023.
  • Year by year, Asset Writedowns and Impairment stood at $250000.0 in 2021, then crashed by 70.4% to $74000.0 in 2022, then surged by 2587.84% to $2.0 million in 2023.
  • Business Quant data shows Asset Writedowns and Impairment for TOI at $2.0 million in Q4 2023, $33000.0 in Q3 2023, and -$3000.0 in Q2 2023.